Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

NCT02456857 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Invasive Breast Carcinoma
Triple-Negative Breast Carcinoma

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Everolimus
OTHER: Laboratory Biomarker Analysis
DRUG: Pegylated Liposomal Doxorubicin Hydrochloride

Sponsor

M.D. Anderson Cancer Center